Whither the ACR20?

Journal of Rheumatology

Volumn 31, Issue 5, 2004, Pages 835-837

  Felson, David T ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; LITERATURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2342452004     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Felson DT. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. J Rheumatol 1993;20:531-4.
2. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
3. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
4. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
5. Felson DT. Assessing the efficacy and safety of rheumatic disease treatments: obstacles and proposed solutions. Arthritis Rheum 2003;48:1781-7.
6. Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum 2003;48:3031-8.
7. Boers M, COBRA Study Group. Combinatietherapie Bij Reumatoide Artritis. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy. Arthritis Rheum 2001;44:2703-4.
8. Albert DA, Huang G, Dubrow G, Brensinger C, Berlin J, Williams HJ. Criteria for improvement in rheumatoid arthritis: alternatives to the ACR 20. J Rheumatol 2004;31:856-66.
9. Anderson JJ, Felson DT, Meenan RF, Williams HJ. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1989;32:1093-9.
10. Pincus T, Strand V, Koch G, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003;48:625-30.
11. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.